Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Yuhan Forms $10 Million Cancer Immune Checkpoint JV with Sorrento Therapeutics

publication date: Mar 3, 2016
Yuhan, a South Korean pharma, has formed a JV with San Diego's Sorrento Therapeutics (NSDQ: SRNE) to develop several Sorrento immune checkpoint antibodies. Yuhan will invest $10 million and own 51% of the JV. Initially, the JV, called ImmuneOncia, will own global rights (excepting the US, Europe and Japan) to one Sorrento drug candidate. The JV will later select two additional Sorrento candidates from a list. Sorrento is developing biosimilar and biobetter antibodies for cancer, inflammation and autoimmune diseases along with clinical-stage CAR-T therapies as treatments for solid tumors. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital